Oculis Holding AG

NasdaqGM:OCS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🕶 Eyewear

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 983.93 M

Share Price

USD 19.28

Avg Daily Volume

36,771

Change (1 day)

-1.03%

Change (1 year)

64.79%

Change (YTD)

13.41%

Oculis Holding AG Share Price Year-To-Date (YTD) return on June 20, 2025: 13.41%

Oculis Holding AG Share Price Year-To-Date (YTD) return is 13.41% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Oculis Holding AG 52-week low Share Price is USD 22.91 on June 20, 2025, which is 18.83% above the current Share Price.
Oculis Holding AG 52-week low Share Price is USD 10.94 on June 20, 2025, which is -43.26% below the current Share Price.
Oculis Holding AG average Share Price for the last 52 weeks is USD 16.37.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqGM: OCS

Oculis Holding AG

CEO	Dr. Riad Sherif M.B.A., M.D.
IPO Date	May 18, 2021
Location	Switzerland
Headquarters	Bahnhofstrasse 7
Employees	49
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🕶 Eyewear 💊 Pharmaceuticals

Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.